Autologous follicle-cell study begins
The study later associated with the RepliCel/RCH-01 development lineage began with 19 participants and evaluated autologous hair-follicle cells.
ClinicalTrials.gov — NCT01286649 ↗Source-linked chronology
Hair cloning development timeline
A chronology of registered human studies, preclinical research and company-reported milestones. Estimated study dates are identified separately from completed events.
Interpretation
What the dates establish
A study start date establishes that a defined investigation has begun. A study completion date does not establish a positive result, regulatory approval or commercial availability. Company announcements are included only as company-reported milestones and are labelled accordingly.
- Registered human study
- Study completed
Historical Phase I/II study completes
The registry records completion of the early study. Its existence establishes clinical investigation, not approval or routine availability.
ClinicalTrials.gov — NCT01286649 ↗ - Adjacent human study
Follicle-derived secretome study begins
Acorn Biolabs began a registered placebo-controlled study of products secreted by cultured follicle-derived cells. The intervention does not contain transplanted cells or engineered follicles.
ClinicalTrials.gov — NCT07107841 ↗ - Recruiting human study
EPI-001 Phase I/II study begins
The registered study evaluates autologous dermal papilla cells in participants with androgenetic alopecia. It is a follicle-rejuvenation study rather than a test of newly manufactured follicular organs.
ClinicalTrials.gov — NCT07618195 ↗ - Preclinical research
OrganTech reports a three-cell regeneration system
A published in-vitro system used epithelial stem cells, dermal papilla cells and an accessory mesenchymal population to support hair-shaft formation and cycling in an experimental model.
OrganTech research release and publication details ↗ - Company-reported clinical evaluation
HairClone reports facility readiness and volunteer selection
HairClone stated that its Guatemala manufacturing facility was operational and that volunteers had been selected for autologous follicle-cell injections. A registered protocol and treatment results were not included in the announcement.
HairClone company announcement ↗ - Registry estimate
Estimated completion of the Acorn secretome study
This is the completion date recorded in the registry. It is an estimate and may change; it is not a treatment-availability date.
ClinicalTrials.gov — NCT07107841 ↗ - Registry estimate
Estimated completion of the EPI-001 study
The registry lists June 2029 as the estimated study completion. Results, regulatory review and any later confirmatory studies would be separate steps.
ClinicalTrials.gov — NCT07618195 ↗
Related evidence